Given the heterogeneous presentation of localized prostate cancer, the possibility of systemic spread that cannot always be excluded and, considering the limitations of PSA as a biomarker, such as lack of cancer specificity, it is important to identify surrogate markers stratifying patients with high risk of treatment failure who should have benefited from early use of androgen deprivation therapy (ADT). The gene discussed is KLK3; the disease is cancer.